Adults with episodic migraine sought for a clinical research study

What is the purpose of the study?

Investigating the possible acute treatment of episodic migraine.

Who can take part?

18–65 year olds who:

• Have a medical history of first symptoms of migraine at the age of 50 or prior
• Have a documented history of episodic migraine for at least 12 months
• Have been unsuccessful with triptans

What will the study involve?

The study is divided into a screening period and a treatment period.

The treatment period starts with a placebo-controlled section where you will be randomised (shuffled) into an active or dummy treatment.

The placebo-controlled phase will last up to 45 days, and you might be eligible for the open label extension phase (additional 12-weeks) where all subjects receive 75mg Rimegepant once daily as needed. Neither you nor the study doctor will know which product you are receiving.

This then is followed by one visit during a two-week follow up period.
You will also be asked to keep a headache diary during the 45 day placebo-controlled phase.

How to take part

If you would like to take part in the study or if you have any questions, please contact headache-research@kcl.ac.uk.

Added: 11 November 2024 | Deadline: 14 February 2025